Gal-1 increases αvβ3-integrin expression and activates FAK/PI3K/AKT signaling in HCC cells, therefore, we examined whether the oncogenic effects of Gal-1 could be reversed by loss of either the αv- or β3-integrin subunits. The gene discussed is AKT1; the disease is hepatocellular carcinoma.